Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 5/20 | 0.49 |
| ▸ | LIPG | Q9Y5X9 | 5/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 6/20 | 0.37 |
| ▸ | NAAA | Q02083 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2897991 | 0.80 | LIPG (0.44) | LPLLIPG | |
| SCHEMBL2083250 | 0.79 | CYP1A2 (0.49) | EPHX1NAAA | |
| SCHEMBL2085239 | 0.78 | CYP1A2 (0.48) | NAAAALDH1A1NPC1RAB9A | |
| SCHEMBL4133101 | 0.77 | NAAA (0.43) | EPHX1NAAAALDH1A1NPC1RAB9A | |
| SCHEMBL4221810 | 0.76 | LIPG (0.43) | LPLLIPG | |
| SCHEMBL3262756 | 0.76 | LIPG (0.43) | LPLLIPG | |
| SCHEMBL4137357 | 0.76 | NAAA (0.58) | EPHX1NAAAALDH1A1NPC1RAB9A | |
| SCHEMBL3210607 | 0.76 | NAAA (0.49) | EPHX1NAAAALDH1A1NPC1RAB9A | |
| SCHEMBL2085864 | 0.75 | LPL (0.47) | LPLLIPGEPHX1NAAAALDH1A1 | |
| SCHEMBL2086284 | 0.73 | LPL (0.46) | LPLLIPGEPHX1NAAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324396-B2 | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | AMGEN INC. (US) | 2012-12-04 | — | — | US | claimed |
| EP-2146954-B1 | METHOD FOR THE SYNTHESIS OF (Z)-3-[2-BUTOXY-3'-(3-HEPTYL-1-METHYL-UREIDO)-BIPHENYL-4-YL]-2-METHOXY-ACRYLIC ACID | GALDERMA RES & DEV (FR) | 2012-10-31 | — | — | EP | claimed |
| EP-2146954-A2 | METHOD FOR THE SYNTHESIS OF (Z)-3-[2-BUTOXY-3'-(3-HEPTYL-1-METHYL-UREIDO)-BIPHENYL-4-YL]-2-METHOXY-ACRYLIC ACID | Galderma Research & Development (FR) | 2010-01-27 | — | — | EP | claimed |
| US-20090054463-A1 | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | AMGEN INC. | 2009-02-26 | — | — | US | claimed |
| WO-2008139121-A2 | METHOD FOR THE SYNTHESIS OF (Z)-3-[2-BUTOXY-3'-(3-HEPTYL-1-METHYL-UREIDO)-BIPHENYL-4-YL]-2-METHOXY-ACRYLIC ACID | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-11-20 | — | — | WO | claimed |
| US-8383652-B2 | Biaromatic compounds that modulate PPAR-receptors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-02-26 | — | — | US | disclosed |
| US-8357819-B2 | Method for the synthesis of (Z)-3-[2-butoxy-3′-(3-heptyl-1-methyl-ureido)-biphenyl-4-yl]-2-methoxy-acrylic acid | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-01-22 | — | — | US | disclosed |
| US-8357819-B2 | Method for the synthesis of (Z)-3-[2-butoxy-3′-(3-heptyl-1-methyl-ureido)-biphenyl-4-yl]-2-methoxy-acrylic acid | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-01-22 | — | — | US | disclosed |
| US-8357819-B2 | Method for the synthesis of (Z)-3-[2-butoxy-3′-(3-heptyl-1-methyl-ureido)-biphenyl-4-yl]-2-methoxy-acrylic acid | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-01-22 | — | — | US | disclosed |
| US-8324396-B2 | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | AMGEN INC. (US) | 2012-12-04 | — | — | US | disclosed |
| EP-2146954-B1 | METHOD FOR THE SYNTHESIS OF (Z)-3-[2-BUTOXY-3'-(3-HEPTYL-1-METHYL-UREIDO)-BIPHENYL-4-YL]-2-METHOXY-ACRYLIC ACID | GALDERMA RES & DEV (FR) | 2012-10-31 | — | — | EP | disclosed |
| EP-2146954-B1 | METHOD FOR THE SYNTHESIS OF (Z)-3-[2-BUTOXY-3'-(3-HEPTYL-1-METHYL-UREIDO)-BIPHENYL-4-YL]-2-METHOXY-ACRYLIC ACID | GALDERMA RES & DEV (FR) | 2012-10-31 | — | — | EP | disclosed |
| WO-2008139121-A2 | METHOD FOR THE SYNTHESIS OF (Z)-3-[2-BUTOXY-3'-(3-HEPTYL-1-METHYL-UREIDO)-BIPHENYL-4-YL]-2-METHOXY-ACRYLIC ACID | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008139121-A2 | METHOD FOR THE SYNTHESIS OF (Z)-3-[2-BUTOXY-3'-(3-HEPTYL-1-METHYL-UREIDO)-BIPHENYL-4-YL]-2-METHOXY-ACRYLIC ACID | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-11-20 | — | — | WO | disclosed |
| EP-1781297-B1 | NOVEL BIAROMATIC COMPOUNDS THAT ACTIVATE PPAR TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RES & DEV (FR) | 2008-10-15 | — | — | EP | disclosed |
| EP-1943213-A2 | PPAR MODULATING BIAROMATIC COMPOUNDS | Galderma Research & Development (FR) | 2008-07-16 | — | — | EP | disclosed |
| US-20070213336-A1 | Biaromatic compound activators of ppargamma receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-09-13 | — | — | US | disclosed |
| EP-1781297-A1 | NOVEL BIAROMATIC COMPOUNDS THAT ACTIVATE PPAR TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | Galderma Research & Development, S.N.C. (FR) | 2007-05-09 | — | — | EP | disclosed |
| WO-2007049158-A2 | PPAR MODULATING BIAROMATIC COMPOUNDS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-05-03 | — | — | WO | disclosed |
| WO-2006018326-A1 | NOVEL BIAROMATIC COMPOUNDS THAT ACTIVATE PPAR TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213336-A1 | Biaromatic compound activators of ppargamma receptors and cosmetic/pharmaceutical compositions comprised thereof | PPARG, PPARA, PPARD | LPL 76/4885LIPG 82/4885EPHX1 2185/4885 |
| US-20090054463-A1 | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | UTS2R, CASR, GPR17 | LPL 4868/4885LIPG 4302/4885EPHX1 2713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.